Article Text

Download PDFPDF
Ongoing pharmacotherapy maintains quality of life benefits in older adults with major depression

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Charles F Reynolds III

Correspondence to: Charles F Reynolds III, MD, WPIC (E1135), 3811 O’Hara Street, Pittsburgh, PA 15213, USA;



Does continuing treatment with combined paroxetine and interpersonal psychotherapy sustain health-related quality of life benefits?


116 people aged 70 years and older who had been diagnosed with major depression, which had responded to treatment with paroxetine and interpersonal psychotherapy. Initially 195 older adults with non-psychotic DSM-IV major depression and 17-item Hamilton Rating Scale for Depression (HRSD-17) score ⩾15 and Mini-Mental State Examination score ⩾17 were recruited and treated with paroxetine and interpersonal psychotherapy. The 151 people who responded (3 consecutive weeks with HRSD-17 score ⩽10) continued to received open treatment for 16 weeks. The 116 people who did not relapse during this period entered the maintenance phase.


University-based clinic for treatment of major depression in old age; recruitment March 1999 to February 2003.


Maintenance treatment with: paroxetine plus clinical management, paroxetine plus monthly interpersonal psychotherapy, placebo plus clinical management, or placebo …

View Full Text


  • Source of funding: National Institute of Mental Health; John A Hartford Foundation. GlaxoSmithKline provided paroxetine tablets for use in the study.

  • ▸ Additional notes and a reference list are published online only at


  • Competing interests: JG has received research funding and support from GlaxoSmithKline and Sanofi-Aventis. He has received research fundingfromUKDepartment ofHealth, Medical Research Council, Economic and Social Research Council and the Stanley Medical Research Institute.